
Overview

Animal Models of Sleep Disorders

Linda A Toth^{1*} and Pavan Bhargava²

Problems with sleep affect a large part of the general population, with more than half of all people in the United States reporting difficulties with sleep or insufficient sleep at various times and about 40 million affected chronically. Sleep is a complex physiologic process that is influenced by many internal and environmental factors, and problems with sleep are often related to specific personal circumstances or are based on subjective reports from the affected person. Although human subjects are used widely in the study of sleep and sleep disorders, the study of animals has been invaluable in developing our understanding about the physiology of sleep and the underlying mechanisms of sleep disorders. Historically, the use of animals for the study of sleep disorders has arguably been most fruitful for the condition of narcolepsy, in which studies of dogs and mice revealed previously unsuspected mechanisms for this condition. The current overview considers animal models that have been used to study 4 of the most common human sleep disorders—insomnia, narcolepsy, restless legs syndrome, and sleep apnea—and summarizes considerations relevant to the use of animals for the study of sleep and sleep disorders. Animal-based research has been vital to the elucidation of mechanisms that underlie sleep, its regulation, and its disorders and undoubtedly will remain crucial for discovering and validating sleep mechanisms and testing interventions for sleep disorders.

Abbreviations: CSF, cerebrospinal fluid; MSLT, multiple sleep latency test; NREMS, non-rapid-eye-movement sleep; REMS, rapid-eye-movement sleep; RLS, restless legs syndrome; OxR, orexin receptor; OSA, obstructive sleep apnea; SOREMSP, sleep-onset rapid eye movement sleep period; SWS, slow-wave sleep

Sleep Disorders

Problems with sleep affect a large part of the general population, with more than half of the people in the United States reporting difficulties with sleep or excessive sleepiness at some time during their lives and with about 40 million affected on a chronic basis.^{113,119} During the past 30 y, knowledge about sleep physiology and the health consequences of sleep loss and sleep disorders has grown substantially. This information—together with growing awareness of the causal or contributory effect of sleep loss and sleepiness on catastrophic accidents, motor vehicular accidents, and performance—has heightened awareness of the effects of insufficient sleep on health, safety, mood, productivity, and quality of life.^{10,56} However, societal and individual efforts to limit or manage sleep loss can be offset by the personal or societal needs or desires to extend waking hours and limit sleep time. Compounding this problem, more than 80 specific sleep disorders have been identified by the American Academy of Sleep Medicine,⁵ and medically defined sleep disorders are prevalent in society. However, for a variety of reasons, many sleep disorders go unrecognized, undiagnosed, or untreated (for examples, see references 134 and 192). Identifying and managing the adverse consequences of sleep loss is further complicated in that personal, subjective estimates of sleep amount and quality, the severity of sleepiness, and the likelihood of falling asleep often correlate

poorly with validated objective measures of sleep, sleepiness, alertness, and performance (for examples, see references 7, 10, 146, 213, 214, 223, and 232).

Sleep is a complex physiologic process that is influenced by many internal and external factors, such that problems with sleep are often related to specific personal circumstances, and complaints about inadequate sleep are rooted (at least to some extent) in the subjective assessment of the affected person. These subjective and circumstantial aspects of sleep complicate the study of sleep disorders in any model other than humans. However, advances in managing the distress and debilitation associated with sleep disorders undoubtedly will require the use of animals for delineation of the underlying physiology of sleep, identification and validation of the causes and mechanisms of sleep disorders, and the development and preliminary testing of new therapeutic approaches. Exemplifying this relationship, 2 landmark independent studies that used either genetically altered mice or dogs with spontaneous narcolepsy discovered that disruptions in orexinergic neuronal systems represent a previously unknown underlying mechanism for narcolepsy and thereby suggested new therapeutic strategies.^{32,121} The current overview considers animal models that have been used to study 4 of the most common human sleep disorders: insomnia, narcolepsy, restless legs syndrome, and sleep apnea (Figure 1).

General Considerations in Studying Sleep in Animals

In most mammals and birds, waking and various stages of sleep can be defined based on electroencephalography (Figure 2;

Received: 17 Sep 2012. Revision requested: 21 Oct 2012. Accepted: 25 Nov 2012.
Departments of ¹Pharmacology and ²Neurology, Southern Illinois University School of Medicine, Springfield, Illinois.
^{*}Corresponding author. Email: ltoth@siumed.edu

| | Insomnia | Narcolepsy | Sleep apnea | Restless legs syndrome |
|------------------|---|---|---|---|
| Definition | Persistent difficulty in falling or staying asleep | Excessive sleepiness associated with cataplexy and other REMS phenomena | Intermittent, somewhat cyclical reductions or cessations in airflow during sleep | Sensorimotor disorder characterized by overwhelming urge to move the legs when they are at rest, usually accompanied by unpleasant sensations |
| Prevalence | 50%, occasional; 22%, frequent | 0.05% of population | 18 million adults in the United States | About 10% of adults in the United States |
| Features | Duration, acute or chronic; etiology, primary or secondary (comorbid); nocturnal timing, sleep onset or early arousal | With or without cataplexy | Central or obstructive; often associated with snoring and obesity | Primary (familial) or secondary (comorbid); worsens with inactivity, including during sleep |
| Adverse outcomes | Unwanted daytime sleepiness or fatigue; cognitive impairment, mood disturbances | Excessive daytime sleepiness, cataplexy, sudden sleep onset, sleep paralysis, hypnagogic hallucinations | Sleep disruption, daytime sleepiness or fatigue; cardiovascular, metabolic, and neuropathologic complications | Uncontrollable leg movements, uncomfortable or painful feelings in legs, interference with sleep |
| Treatments | Sleep hygiene, hypnotic medications, cognitive behavioral therapy | Stimulant and antidepressant medications, sodium oxybate | Weight loss, continuous positive airway pressure, oral appliances, sleep, hygiene, surgery | Diet, exercise, medication (dopamine agonists, opioids) |

Figure 1. Common sleep disorders.

reviewed in reference 210). Electroencephalography provides an objective and functional marker of sleep, can be measured in freely moving or naturally sleeping animals under controlled laboratory conditions or in a naturalistic environment, and supports studies of the pharmacologic and physiologic manipulation of sleep.¹⁵⁹ Electroencephalography is often used to assess sleep in combination with measurement of body and brain temperature, other physiologic systems (for example, respiration), brain and blood chemistry, and brain functioning.⁴⁸ However, specific electroencephalography-based features of sleep vary across species; for example, some species show single-hemisphere sleep, and some monotremes appear to lack features that characterize rapid-eye-movement sleep (REMS) in placental and marsupial mammals.^{2,116,117} In contrast to birds and mammals, reptiles and amphibians have higher amplitude cortical activity during waking states than they do in quiescent states, and they do not appear to have REMS (reviewed in references 2 and 181). However, although electroencephalography-defined sleep architecture can vary among species, many features, including key homeostatic, circadian, and neurochemical modulations of sleep, are similar across species.^{159,217}

In addition to an electroencephalography-based definition, sleep can be defined behaviorally as a regulated state of reduced movement and sensory responsiveness (that is, behavioral quiescence and an elevated arousal threshold that respond to homeostatic regulation).^{2,231} Behaviorally defined states that appear analogous to electroencephalography-defined sleep have been identified in both mammalian and nonmammalian organisms, the latter including fish, flies, nematodes, and birds.^{41,196}

The daily amount of sleep and its placement within the 24-h day are fundamental characteristics of sleep in animals and have been evaluated in over 150 animal species, including invertebrates, fish, amphibians, reptiles, birds, and 14 orders of mammals in over 200 studies using behavioral methodology or electro-

encephalography (or both) in laboratory and field studies.^{27,231} However, the daily duration, cyclical organization, diurnal timing, and other features of sleep vary extensively among animal species.^{2,27,45,231} Indeed, even inbred strains of laboratory mice show variation in these properties of sleep.^{80,211} Furthermore, commonly used rodents generally are preponderantly awake during the dark phase and asleep during the light phase. Species with a higher basal metabolic rate on a body-weight basis appear to spend a relatively larger total percentage of time in slow-wave sleep (SWS), suggesting an energy conservation role for this sleep state.^{115,230} In comparison, other species spend relatively less time in REMS, suggesting a diminished neurophysiologic role for REMS in those animals.²³¹ However, such species-related comparative assessments of sleep and its features may generate different relationships and conclusions depending on how the analysis is conducted and interpreted.^{117,182,183,197,198} For example, when controlled for phylogeny, an assessment based on 4 common sleep indices (body mass, brain mass, basal metabolic rate, and gestation period) and an ecological variable (a measure of predation risk based on vulnerability associated with the sleep site) found interspecies support for a neurophysiologic role for REMS, but no support for an energy conservation function for SWS,^{116,117} in contrast to previous analyses that did not consider phylogeny.^{230,231}

Effective use of animals to study normal sleep and sleep disorders must consider known similarities and differences between human and animal sleep patterns (Figure 3). For example, in adult humans and in nonhuman primates, the circadian distribution of sleep tends to be consolidated and normally monophasic (perhaps diphasic with consideration of napping and segmented sleep), whereas it is polyphasic and relatively fragmented in rats, mice, and cats. Therefore, within a night's sleep, humans pass through 4 to 6 cycles of nonrapid eye-movement sleep (NREMS; often referred to as SWS in animals) and

| | Behavioral features | | | Electrophysiologic features | | |
|-----------|---|----------------------------|-----------------------------------|---|------------------------|-------------------|
| | Thought | Movement | Eyes | EEG | Electromyogram | Electrooculogram |
| NREMS-SWS | Some mental activity; no memory unless awakened | Infrequent, involuntary | Closed; slow or no movement | Synchronized, slow frequency, high amplitude | Reduced | Slow or absent |
| REMS-PS | Illogical mental activity; memory only if awakened | Inhibited | Closed; rapid movement | Desynchronized, fast frequency, low amplitude | Inhibited | Rapid |
| Waking | Logical mental activity; memory | Frequent, voluntary | Open; directed movement | Desynchronized, fast frequency, low amplitude | Present, purposeful | Present, directed |

Figure 2. Behavioral and electrophysiologic features of vigilance states. PS, paradoxical sleep

| | Human | Rat | Mouse | Cat | Dog |
|-----------------------------|------------------------|------------|------------|------------|------------|
| Primary diurnal sleep phase | Dark | Light | Light | Dark | Dark |
| Sleep pattern | Monophasic or diphasic | Polyphasic | Polyphasic | Polyphasic | Polyphasic |
| Daily sleep duration | 7–8 h | 12–15 h | 12–15 h | 12–13 h | 9–14 h |
| Length of sleep bouts | 6–8 h | 10–14 min | 2–4 min | 78 min | 45 min |

Figure 3. General characteristics of normal sleep in humans and 4 commonly used model species.^{27,51,108,132,212,231}

REMS (also referred to as paradoxical sleep, due to the associated cortical activation), whereas in rats, mice, and cats, NREMS–REMS cycles are much shorter and occur periodically throughout the 24-h day. Furthermore, environmental factors, including temperature and photoperiod, can substantially alter these parameters.²⁷ For example, a recent study reported that mice living in a natural environment are not explicitly nocturnal, exhibit feeding activity that is predominantly and sometimes exclusively diurnal, and show a negligible modulatory influence of specific genes on activity timing as compared with seasonal influences.⁴³

The restorative properties of sleep depend on its duration, quality, and continuity. For example, sleep fragmentation, as occurs in persons with sleep apnea, disrupts normal sleep architecture, reduces the amount of time spent in the deeper stages of sleep, and reduces the restorative benefit of sleep. Although patients with sleep apnea may not complain of insomnia, the impaired continuity of their sleep causes a variety of problems, including fatigue and daytime sleepiness. In comparison, sleep in rodents is highly fragmented even under normal conditions, with normal individual sleep bouts of less than 5 min in mice.

Despite many differences in sleep between animals and humans, the many commonalities have made animal studies fundamental to past and future research on sleep.^{48,231} Translational animal models have supported the investigation of sleep and sleep disorders in ways that are not possible in human volunteers, thereby expanding our understanding of sleep neurophysiology and regulation and facilitating the development of new treatments for sleep disorders.^{48,159}

Insomnia

Insomnia is the most commonly reported sleep-associated problem, affecting as much as 50% of the adult population periodically and 10% to 15% chronically.¹⁴¹ Insomnia is characterized by complaints that include difficulty in falling asleep, frequent awakening from sleep, waking too early and having trouble falling back to sleep, and nonrestorative sleep. These problems occur despite adequate opportunity to sleep and result in daytime sleepiness or fatigue and performance impairment. Insomnia can be characterized in terms of duration (acute or chronic), cause

(primary or secondary), type (psychophysiologic, paradoxical, inadequate sleep hygiene, comorbid, and idiopathic), and timing during the night (initial or onset, middle, late, or mixed).¹⁶² Several theoretical frameworks have been developed to explain the basis for insomnia (reviewed in reference 162), and available animals models of insomnia generally derive from the demonstrated efficacy of known approaches to insomnia management in those models.¹⁸⁴ The growing body of information on the physiology of sleep supports a reasonably circumscribed list of general pathophysiologic mechanisms of primary insomnia that encompass 4 broad candidate areas: 1) disruption of sleep homeostatic regulation; 2) disruption of the circadian clock; 3) disruption of intrinsic systems responsible for the expression of sleep; and 4) enhancement of extrinsic systems that can alter normal sleep–wake regulation.¹⁸⁴

A model that incorporates several of these theoretical features involves exposure of rats to a stressful environment; this experience is followed several hours later by sleep disturbances similar to those of people with stress-induced insomnia (prolonged sleep latency, reduced sleep duration, frequent arousals and fragmentation of sleep, high-frequency electroencephalographic activity during NREMS).²⁸ Careful and detailed examination of behavior, immunohistochemistry, and specific brain lesions indicates that rats exposed to this situation develop simultaneous activation of arousal and sleep-promoting regions in the brain.²⁸ In particular, specific limbic regions appear to activate brainstem arousal systems and subsequently the cerebral cortex, generating high-frequency activity in the electroencephalogram.²⁸ Similarly, insomnia in people can occur in association with inappropriate arousal from sleep, increases in the high-frequency component in the electroencephalogram, abnormal hormone secretion, and autonomic and metabolic activation in both brain and the periphery.¹⁹

Rodent genetic models purported to represent insomnia have been proposed on the basis of strain-related differences in the 24-h amount and diurnal distribution of sleep.^{14,44,80,180} For example, as compared with other mouse strains, DBA/2J mice spend more time awake during a 24-h period, have relatively low electroencephalographic δ power (theoretically related to low sleep

drive) both over the 24-h day and during the light (rest) phase, and show a relatively high number of brief awakenings and SWS episodes.^{63,80} These characteristics (a low amount of sleep that is shallow and fragmented) resemble those of some patients with insomnia,⁸⁰ suggesting the possibility that DBA/2J mice may be a useful model of insomnia.

Various strains of *Drosophila* created by laboratory selection also vary in the amount, pattern or proportion of time spent in a behavioral state that appears analogous to electroencephalography-defined sleep in mammals.¹⁹⁵ So-called insomnia-like (ins-l) flies sleep less than do normal flies, appear to have difficulty initiating and maintaining sleep, and show evidence of daytime cognitive impairment.¹⁹⁴ These flies also are hyperactive, are hyperresponsive to environmental perturbations, and show other features that may be related to their sleep phenotype.¹⁹⁴ Whole-genome profiling of ins-l flies has identified differential expression of at least 2 genes that are upregulated in human subjects after acute sleep deprivation.¹⁹⁴ Ins-l flies may be useful for the identification of genes and molecules that contribute to sleep regulation, genetically driven sleep need, and insomnia.¹⁹⁴

Administration of caffeine has been proposed as a simple and effective model of sleep-onset insomnia. The effects of caffeine on sleep in humans and animals include increased arousal, prolonged latency to sleep onset, reduced total sleep time and efficiency, and reduced build-up of sleep pressure during waking.^{18,96,109,160,169,184,227} Furthermore, sleep-promoting agents attenuate or reverse caffeine-induced sleep disruptions in rats and people.^{151,160}

Some circadian clock genes influence sleep (reviewed in reference 86). For example, a point mutation in the human clock gene *Per2* produces the rare advanced sleep-phase syndrome, whereas a functional polymorphism in *Per3* is associated with the more frequent delayed sleep-phase syndrome.⁸⁶ Furthermore, an association study revealed a higher recurrence of insomnia in patients homozygous for Clock polymorphisms.^{86,193} Selective breeding of mice was used to create an early-running (indicative of spontaneous early awakening) genetic variant.²²⁵ In these variant mice, the onset of the daily wheel-running bout precedes dark onset by several hours, and pharmacologic treatment at appropriate circadian times normalizes diurnal patterns of running.²²⁵

Finally, some models using brain lesions also result in at least temporary reductions in sleep that may mimic some features of insomnia. For example, lesions of the ventrolateral preoptic nucleus, which contains neurons that are active during sleep, cause significant reductions in both the amount and depth of NREMS; these effects persist for at least 3 wk after the lesion.¹²⁵

An ideal animal model of insomnia would mimic the main characteristics of human insomnia: the animal would display reductions in the amount or quality of sleep at times when sleep would normally be expected and would accrue sleep debt or display sleepiness or tiredness during the normal active phase. Therefore, modeling insomnia in animals requires the creation of a situation in which the subject does not initiate sleep at the appropriate circadian phase, despite being given sufficient opportunity to sleep, and subsequently develops a sleep debt, or a need for recuperative sleep. Few (if any) models convincingly achieve these conditions. For example, in typical experimental sleep deprivation, animals are actively prevented from engaging in sleep despite having the desire and ability to sleep. Rodent models of disrupted sleep generally involve perturbation of the animal or its situation, commonly via imposition of a stressor (for

example, immobilization, an altered environment, social stress, fear and fear conditioning, sensory stimulation; reviewed in reference 180). Finally, consideration of the temporal organization of sleep and waking is crucial to developing models for testing sleep-promoting drugs. For example, because many commonly studied rodent species are relatively active during the dark phase and somnolent during the light phase, administration of sleep-inducing agents during the light phase may mask or minimize sleep-inducing properties, whereas administration during the dark phase would test a drug's effects in animals that are active and showing little or no sleep pressure.

The question remains of whether currently available models actually represent insomnia, because one cannot determine whether the animals trying unsuccessfully to sleep or simply are not sleeping. Furthermore, people with insomnia often report sleep problems that are not confirmed on polysomnography, indicating a substantial subjective perceptual component in many cases of this disorder.^{90,223,232} Nonetheless, data obtained from model systems clearly have extended our understanding of the brain mechanisms that underlie sleep and wakefulness and the processes that contribute to the homeostatic and circadian regulation of sleep. This knowledge would be unavailable without the careful assessment of sleep in animals.

Sleep Apnea

Sleep-disordered breathing refers to intermittent, somewhat cyclical reduction or cessation of airflow during sleep. This common condition affects at least 18 million Americans.⁵⁰ In the specific disorder known as sleep apnea, airflow stops during sleep. The 2 forms of sleep apnea are obstructive and central, which respectively occur with or without obstruction of the upper airway; obstructive sleep apnea (OSA) is by far the most common type, often occurring in association with snoring. In the presence of a collapsible airway, sleep-induced loss of tonic input to the upper airway dilator muscle motor neurons allows the pharyngeal airway to collapse.⁵⁰ The sleeping subject generally reacts to this airway obstruction by awakening; sleep then resumes, leading to repeated cycling of sleep, intermittent hypoxia, and arousal throughout the night.⁵⁰ Numerous comorbid conditions, including diabetes and cardiovascular disease, are associated with sleep-disordered breathing and OSA. Predisposing factors are obesity, large necks in men, menopause in women, and physical abnormality of the upper airway. The health consequences of OSA include systemic and pulmonary hypertension, stroke, coronary artery disease, and cardiac arrhythmias.⁵⁰ In addition, intermittent hypoxemia and sleep disruption can negatively affect insulin sensitivity and glucose regulation and may contribute to the development of metabolic syndrome independent of obesity.²¹⁶ Neurocognitive effects of OSA include daytime sleepiness and impaired memory and concentration; persistent (perhaps permanent) cognitive impairment and neural injury may develop in association with sleep apnea despite long-term therapy, particularly when sleep apnea develops in association with or as a consequence of concurrent comorbid conditions.^{50,120,216}

Sleep-disordered breathing and OSA are not reported frequently in animals but do appear spontaneously in some species and strains. A natural animal model of OSA is English bulldogs, which have been used to study upper airway anatomy and physiology and the pharmacologic treatment of OSA. English bulldogs have an enlarged soft palate and narrow oropharynx and

display many of the clinical features of OSA, including snoring, sleep-disordered breathing, oxyhemoglobin desaturation during sleep, frequent arousal from sleep, and hypersomnolence with shortened sleep latencies.^{91,92} However, OSA in English bulldogs is not related to obesity, as it often is in humans. Obese Yucatan minipigs have been proposed as a model of obesity-related sleep apnea; obese pigs exhibit considerably more apnea and oxyhemoglobin desaturation than do their lean counterparts.¹²³ Although the upper airways of nonhuman primates have structural and functional similarities to those of humans, spontaneous OSA has not been reported in any nonhuman primate species to date to our knowledge. However, cynomolgus macaques that received intradermal liquid collagen injections in the uvula, tongue, and lateral pharyngeal walls developed hypopnea and reduced REMS.¹⁶³ Sprague–Dawley and spontaneously hypertensive rats exhibit sleep-related central apnea that has been exploited experimentally.^{29,30}

Noninvasive models of intermittent hypoxemia expose animals to repetitive hypoxia and oxygenation, which occur in both obstructive and central apnea (reviewed in reference 49). Depending on the species, animals are either ventilated with a mask or placed in a ventilated cage or chamber; in either case, they breathe nitrogen-enriched air (to create hypoxia) alternating with oxygen or normal air.⁴⁹ By creating intermittent hypoxemia, these models allow evaluation of oxygen desaturation, hypercapnia, sustained hypoxia, and sleep fragmentation.^{77,168,186} The models typically apply the stimulus of intermittent hypoxemia during the sleep-dominant phase of the diurnal cycle and create moderate to severe oxygen desaturation, thereby mimicking severe forms of human sleep apnea (reviewed in reference 49). In human patients, the severity of sleep apnea is assessed based on both desaturation of arterial oxygen and the frequency of respiratory events (apnea or hypopnea).^{4,49} Therefore, modeling different severities of sleep apnea requires reproduction of both the appropriate frequency of intermittent hypoxemia cycles and sufficient oxygen desaturation to be comparable to those in human patients. An advantage of intermittent hypoxemia models is that they permit exposures that can be extended over months, allowing the investigation of chronic consequences that might occur in humans.^{187,188,235}

OSA has been modeled in a variety of species by using surgical tracheostomy and subsequent intermittent occlusion of the endotracheal tube.^{25,71,73,105,110,166,190,221} These models produce predictable, reliable, and modifiable obstructive apneas that are compatible with concurrent neural manipulation and hemodynamic measurements. Rodents are often exposed to hypoxia for a fixed period of time during the light (somnolent) phase, with normoxia during the dark (active) phase. Although many studies do not link exposure to intermittent hypoxemia with sleep or sleep onset, some studies monitor the animal's sleep–wake state and generate airway obstruction in association with sleep and release this constraint during arousal.^{24,87,101} For example, one study produced obstructive apnea in conscious rats by using an inflatable balloon implanted in the trachea.¹⁹¹ When deflated, the tracheal implant did not notably impair normal breathing, yet apneic episodes of as long as 16 s in duration could be created during sleep.¹⁹¹

Mice have increasingly been used to study interactions between sleep and respiration. C57BL/6J mice show spontaneous apnea, postsigh apnea, and irregular breathing with apnea during reoxygenation after acute hypoxia.²²⁶ These mice have been used, for example, to assess the relationships among obesity, age, and

pharyngeal mechanical and neuromuscular control.¹⁶⁷ C57BL/6J mice can also be used to develop pharmacologic and genetic approaches to improving irregular breathing and apnea.²²⁶ New Zealand obese and New Zealand white mice and respiratory-gated MRI of the pharynx have been used to determine the effect of obesity on pharyngeal airway size during inspiration and expiration.^{21,22} As compared with lean New Zealand white mice, New Zealand obese mice have a significantly smaller airway, greater parapharyngeal fat pad volumes, and a greater volume of other upper-airway soft tissue structures.²² Pharyngeal airway cross-sectional area is greater during inspiration than expiration in New Zealand obese mice, whereas the reverse occurs in New Zealand white mice, supporting the idea that pharyngeal airway patency in obese subjects depends on airway dilation during inspiration and may be vulnerable to sleep-associated loss of neuromuscular pharyngeal activation.^{21,22}

Animals have been used to study the neurochemical regulation of pharyngeal motor neuron activity and airway patency and, because oxyhemoglobin saturation patterns correlate with neural injury, have facilitated investigation of how OSA can cause neurobehavioral and cognitive impairment independent of comorbidities.^{50,120,216} Neurons and neuronal groups that are more metabolically active are typically the most vulnerable to hypoxic injury.¹²⁰ Long-term exposure of adult mice to cycles of hypoxia and reoxygenation results in irreversible impairments that develop in association with vacuolization in the perikarya and dendrites and markedly impaired *c-fos* activation in both noradrenergic locus coeruleus and dopaminergic ventral periaqueductal gray wake neurons, with a 40% loss of catecholaminergic wake-related neurons after 6 mo of exposure.²³⁵ In contrast, cholinergic, histaminergic, orexinergic, and serotonergic wake-related neurons seem unperturbed.²³⁵ The use of animals to identify molecular pathways for oxidative, inflammatory, and organelle injury related to neural dysfunction provides an avenue for the development of interventions that may prevent or even reverse neural injury from sleep apnea.^{120,216}

Current animal models of intermittent hypoxemia have several drawbacks. In many cases, the models mimic severe human OSA and may be less applicable to most clinical OSA.⁴⁹ In addition, animals exposed to intermittent hypoxemia develop hypocapnia, whereas human OSA is characterized by hypercapnia.^{49,103} Although CO₂ supplementation in rats does not modify hypertensive effects of intermittent hypoxemia,⁷⁸ CO₂ levels may influence other effects of intermittent hypoxemia and OSA. Furthermore, human OSA typically is associated with obesity, which is not always considered in animal studies. In addition, OSA causes sleep fragmentation, which may have independent effects on metabolism. Models for studying OSA-associated sleep fragmentation have been developed in animals.^{13,25,88,165,218} However, these models may not achieve reliable or reproducible arousals during the course of chronic exposure; for example, sleep changes induced by long-term exposure to intermittent hypoxemia in animals may be less durable than are effects on blood pressure.^{76,77,88,95,105,147,168,219} Thus, exposure of animals to intermittent hypoxemia produces repeated arousals and changes in sleep architecture that are comparable to those in clinical OSA, yet the effects may not be persistent, limiting their use for studying long-term metabolic consequences of OSA.

Narcolepsy

Narcolepsy is characterized by 4 cardinal symptoms: excessive daytime sleepiness, cataplexy, sleep paralysis, and hypnagogic hallucinations (reviewed in reference 1). Cataplexy is the most characteristic feature of narcolepsy and consists of sudden muscle atonia during wakefulness. Cataplexy is triggered by emotions and varies in presentation, ranging from complete postural collapse to attacks that affect only facial muscles, neck, arms or legs. Episodes of cataplexy last from a few seconds to 10 min and are associated with a waking or a REMS-like electroencephalogram. Most narcoleptic patients also have disturbed sleep, including sleep fragmentation, prolonged NREMS-REMS cycles, periodic limb movements during sleep, and comorbidities such as OSA. The excessive daytime sleepiness of narcolepsy is associated with episodes of an irresistible urge to sleep (sleep attacks).

Narcolepsy is clinically categorized as occurring with cataplexy, without cataplexy, or secondary to another medical disorder. The diagnosis usually requires patient assessment with polysomnography both at night and during a multiple sleep latency test (MSLT).⁵ The MSLT involves 5 nap opportunities scheduled 2 h apart during the day time, beginning 1.5 to 3 h after awakening. Key diagnostic features of the MSLT are the latencies of sleep onset and REMS. If REMS occurs in less than 15 min, then the epoch is defined as a sleep-onset REMS period (SOREMSP). A MSLT consistent with narcolepsy reveals a mean sleep latency of less than 8 min and 2 or more SOREMSP after minimally sufficient sleep on the previous night.

The most likely cause for narcolepsy has been identified as the degeneration of hypothalamic neurons that contain the peptide orexin, which is also called hypocretin. The landmark discovery of the role of orexin in narcolepsy was based on the study of narcoleptic dogs and observations of orexin-deficient mice.^{32,121} Narcoleptic patients have low levels of orexin A in their CSF.²⁰ Two other peptides (dynorphin and neuronal-activity-related pentraxin [NARP]) colocalize with orexin in neurons and may contribute to narcolepsy.⁴² In addition, most narcoleptic patients with cataplexy are positive for a specific MHC class II allele, HLA-DQB1*0602.¹²²

Canine models. In addition to humans, spontaneous narcolepsy has been described in dogs, cats, and horses.^{57,106,127,138,202} Affected dogs show attacks of cataplexy that may be partial or involve full collapse; electroencephalographic recordings show normal electrical activity and sleep stages but also document SOREMSP.¹³⁸ Canine narcolepsy with cataplexy has now been identified in several breeds, with Doberman pinschers and Labrador retrievers showing familial forms (autosomal recessive) and other breeds showing sporadic narcolepsy.^{31,70,79} Familial cases generally have early onset with mild symptoms, whereas sporadic cases have varied onset and more severe symptoms.³³ Cataplexy in dogs is evaluated with a highly standardized food-elicited cataplexy test in which 12 pieces of canned dog food are placed on the ground in a semicircular pattern at 30-cm distances.¹⁷⁹ A normal dog eats all of the food in approximately 10 s, whereas a narcoleptic dog exhibits episodes of partial or complete cataplexy before eating all the food. Another test involves play-elicited cataplexy, in which 2 dogs are brought into a room and allowed to freely interact with each other and with toys.¹⁷

Three stages of cataplexy have been described in narcoleptic dogs.¹⁰⁷ The first stage consists of muscle atonia, a waking-like electroencephalogram, and retained visual tracking; the second

stage is characterized by REMS with hippocampal theta activity; and the third stage shows mixed-frequency and -amplitude electroencephalographic activity prior to a transition to wakefulness or sleep. Sleep recordings have revealed similar total sleep time in normal and narcoleptic dogs.¹⁰² However, narcoleptic dogs spend more time in a drowsy state and, during the canine MSLT, have a shorter sleep latency and higher frequency of SOREMSP than do normal dogs.¹⁴⁹ Human narcoleptic patients develop altered ultradian rhythms of sleep, whereas dogs do not.^{26,149}

The search for a culprit gene for canine narcolepsy ultimately identified the type II orexin receptor gene (*OxR2*); different mutations of *OxR2* were identified in familial canine narcolepsy in Doberman pinschers, Labrador retrievers and a dachshund family, all of which led to a nonfunctional receptor.¹²¹ Sporadic cases of canine narcolepsy did not have a similar mutation, but did have low levels of orexin in the CSF.⁹⁷ In addition to the genetic mutation, other factors may play a role in producing canine narcolepsy. For example, Doberman pinschers with the *OxR2* mutation show evidence of increased microglial expression of MHC II at about 1 mo of age, coinciding with neuronal degeneration in the amygdala and basal forebrain.²⁰³ Treating these narcoleptic dogs with antiinflammatory and immune-suppressive agents beginning before 3 wk of age doubled the time to disease onset and reduced time spent in cataplexy by 90%.¹⁷

Mouse models. Mice that were genetically engineered to lack orexin were observed to have abrupt transient episodes of behavioral arrest during the dark (active) phase.³² During these episodes, mice developed electroencephalographic and electromyographic patterns similar to those present during REMS or NREMS with sleep spindles.³² These mice also had fragmented NREMS, greater amounts of REMS during the dark phase, decreased REMS latency, and multiple SOREMSP.³² Therefore, the mice show many similarities to human and canine narcolepsy. A consensus report has defined murine cataplexy as an abrupt episode of nuchal atonia lasting at least 10 s, with θ activity dominating the electroencephalogram during the episode, and video recordings documenting immobility; at least 40 s of wakefulness must precede the episode.¹⁸⁹ Mouse cataplexy can be triggered by social interaction, locomotor activity, anticipation of food, ultrasonic vocalizations, wheel running, and group housing.^{36,65,158}

Like narcoleptic Dobermans, *OxR2* knockout mice are only mildly symptomatic; their patterns of sleep and behavior correspond to the excessive daytime sleepiness and cataplexy of human narcolepsy.²²⁴ *OxR1* knockout mice have moderate sleep fragmentation without cataplexy, whereas mice that lack both *OxR1* and *OxR2* have a phenotype similar to that of orexin null mice.^{137,224} A caveat of studies using mice with constitutive gene deletions is that phenotypes may be confounded by developmental compensation, and therefore administration of inhibitors of OxR has been used to model narcolepsy; however, neither an *OxR1* selective nor a dual *OxR* antagonist produced cataplexy in rodents, although they did increase REMS.²³ In addition to fragmentation of sleep and waking, mice with ablation of orexinergic neurons or *OxR* develop reductions in locomotion, feeding, drinking, and energy expenditure.²³⁴

In human narcolepsy, the loss of dynorphin and NARP signaling from orexin neurons likely contributes to the production of the disease.⁴² Therefore, the most accurate model may require loss of orexin neurons rather than loss of only the orexin gene. A cytotoxic transgene, the N-terminal truncated cDNA for human

ataxin 3, can be used to ablate orexin neurons.⁸⁹ Mice with ablation of orexin neurons exhibit behavioral arrest, sleep fragmentation, and SOREMSP, as well as obesity beginning at 12 to 15 wk of age.⁸⁹ Genetic background, diet, and sex all appear to influence the phenotype of narcoleptic mice.⁸¹

Rat models. Injection of orexin B conjugated to the ribosomal toxin saponin into the rat hypothalamus leads to loss of over 90% of orexinergic neurons, with concurrent loss of other substances such as melanocyte concentrating hormone.⁸² Rats treated in this manner spend more time in NREMS and REMS during the dark phase but spend less time in REMS during the light phase, with multiple SOREMSP.⁸²

Transgenic rats that express a human ataxin-3 fragment under control of the human prepro-orexin promoter (orexin-ataxin 3 rats) develop almost complete loss of orexin neurons by 17 wk of age in association with sleep fragmentation, less wakefulness during dark phase, changes in REMS duration during both light and dark phases, a shortened REMS latency, multiple SOREMSP, and brief periods of atonia and postural collapse in association with electroencephalographic characteristics of wakefulness, resembling cataplexy.¹⁶ Orexin levels in the CSF fall dramatically by 2 to 4 wk, with levels in regions of the cortex of less than 1% of levels in control rats.²³³ The orexin-ataxin 3 rats retain some orexin neurons in the lateral hypothalamus and can double their CSF orexin levels in response to sleep deprivation, but even these elevated levels are still much lower than are basal levels in control rats.¹⁶

Another method of reducing levels of orexin or orexin receptors is through use of antisense RNA or RNA interference technology. In contrast to chemical destruction or gene deletion, the effects of interfering RNA are selective and reversible and have a fast onset. A study using microdialysis perfusion of *oxR2* antisense RNA into the pontine reticular formation of rats for 3 d produced more time in REMS and more episodes of cataplexy.²⁰⁸ Targeting of prepro-orexin mRNA by injecting short interfering RNA into the perifornical hypothalamus of rats resulted in suppressed expression of preproorexin, increased REMS during the active phase and cataplexy-like behavior, with no effect on NREM sleep.³⁵ Microinjection of small interfering RNA targeting the orexin type 1 receptor into the locus coeruleus of rats increased REMS during the dark phase.³⁴

Restless Legs Syndrome

Restless legs syndrome (RLS) is a common disorder, with a reported prevalence of 5% to 15% in the general population.²²⁸ RLS is more common in women than in men, and although it may develop at any age, it is more common in older adults.¹⁵⁰ RLS appears to have a familial predisposition.⁶² The essential criteria for the diagnosis of RLS are 1) an urge to move the legs, accompanied or caused by unpleasant sensations in the legs; 2) onset or worsening of the urge during rest or inactivity; 3) partial or total relief by movement; and 4) worsening of symptoms during the evening or night as compared with the day.³

The underlying pathophysiology of RLS has not yet been elucidated completely. However, human studies have revealed 2 major impairments. First, functional brain imaging and autopsy studies have revealed abnormalities of the dopaminergic system.^{39,60} In addition, dramatic improvement occurs after administration of dopaminergic agonists and symptoms are worsened by dopaminergic antagonists, supporting involvement of the dopaminergic

system.²²⁸ Second, the severity of RLS symptoms is inversely correlated with iron levels in serum and CSF.¹³⁹ CSF ferritin is decreased in patients with RLS, and imaging studies indicate reduced iron content in the striatum and red nucleus.¹³⁹ In addition, autopsies of brains of humans with RLS have shown reduced ferritin and iron staining and increased transferrin staining but decreased numbers of transferrin receptors.³⁸ Furthermore, serum ferritin levels correlate strongly and inversely with RLS symptom severity,⁵⁹ although because not everyone with iron deficiency develops RLS, other factors must also be important. The site of pathology in RLS within the nervous system remains elusive; however the preponderance of lower extremity involvement and development of RLS after spinal cord injury suggests involvement of the spinal cord, the circadian pattern of variation of symptoms suggests an associated dysfunction in circadian control areas, and the unpleasant sensory component suggests malfunction of antinociceptive mechanisms.^{9,207}

Based on these features, several types of animal models have been evaluated with regard to RLS. One category involves animals with dopamine-related deficits in brain function. For example, the hypothesis that the diencephalic spinal tract (A11 dopamine cell cluster) is involved in the pathogenesis of RLS^{37,154,171} has been tested by using the neurotoxin 6-hydroxydopamine to induce bilateral depletion of diencephalic A11 dopaminergic nuclei in rats.^{154,155} Although some of the physical signs and response to treatment in rats were consistent with clinical RLS in humans,^{154,155} the subjective aspects (for example, 'unpleasant sensations' or 'an urge to move') cannot be convincingly assessed in rats, and therefore the lesion may only partially mimic the clinical features of RLS. Dopamine systems may also be relevant to the circadian activity abnormalities of RLS because the suprachiasmatic nucleus of the hypothalamus projects to the A11 dopaminergic nucleus.

Mice with iron deficiency show marked increases in wake time in the 4-h period prior to light onset, yet their sleep and wake time is normal during the 12-h light period.⁴⁷ The period of increased wakefulness corresponds to the diurnal time point at which RLS symptoms maximally disrupt sleep onset and progression in humans, suggesting that iron-deficient mice may provide a potentially useful animal model for RLS.⁴⁷

Finally, models of dopamine deficiency and iron deficiency have been combined. For example, among mice maintained on iron-deficient diets prior to the induction of bilateral lesions of the A11 nucleus by using 6-hydroxydopamine, locomotor activity was greatest in the group with both iron deprivation and lesions, and this hyperactivity was ameliorated by appropriate pharmacologic treatment.^{128,170} In a genetic model, D3 receptor knockout mice display a phenotype consistent with the symptoms of RLS, iron-deficient D3 receptor knockout mice show greater acute and persistent pain responses than those in control mice, and responses are greater in mice with both deficiencies.⁵⁵ Furthermore, iron-deficient mice show a period of increased locomotor activity before the light (rest) phase; this timing resembles the increased restlessness of RLS patients prior to sleep.⁵⁵ Iron-deficient D3 receptor knockout mice develop this increased activity 3 to 4 h earlier than do mice with only iron deficiency.⁵⁵

In summary, several animal models of RLS have been proposed. The key features include iron deficiency and dopaminergic deficit either due to genetic or pharmacologic manipulation. The changes in locomotor activity, circadian rhythm, and sensory responses in these models seem to mimic some of the clinical features of RLS.

However, RLS is a subjective clinical diagnosis based on symptoms reported by patients. The urge to move, unpleasant sensations, and amelioration of these perceptions by movement are key features that pose a major challenge for additional investigation of this condition in animal models.

Other Animal Models for the Study of Sleep Physiology and Sleep Disorders

Increasing awareness of the importance of sleep to normal health and functioning, together with growing numbers of new research tools and genetically altered animals, has led to the identification of animals with sleep abnormalities that have not yet been linked to specific sleep disorders. However, such models may nonetheless be valuable in contributing to improved understanding of sleep physiology and pathophysiology and may eventually become associated with specific sleep disorders. For example, the study of 'hippocampal ripples' in rodents could lead to improved understanding of the mechanisms that link sleep to learning and memory.^{64,83,209,222} Numerous other models offer similar possibilities, including, for example, mice that show alterations in normal sleep, behavioral features such as anxiety, and various gene deletions or insertions.^{8,58,75,100,143} Other approaches can also be used to model human sleep disorders. For example, rats with spinal cord injury show leg movements during sleep and may be a model for the study of periodic leg movement during sleep in paraplegic patients.⁶⁶ Male and female rodents can be evaluated to determine sex-associated effects in sleep processes and sleep disorders (for examples, see references 6, 140, and 161), as some sleep disorders show a significant sex-associated bias.^{61,164,172}

Management of Animals Used to Study Sleep Disorders

Many external and internal factors can influence sleep in animals and people. Environmental cues and stimuli that are relevant to the use of animals for the study of sleep and sleep disorders include light exposure and photoperiod (for example, variation in light intensity or in the duration of the light and dark phases within each 24-h cycle, the use of light:dark cycle lengths that exceed or are less than 24 h, exposure to constant dim light or darkness, exposure to light during the dark phase, on-off ramping of lighting to mimic dawn-dusk), ambient temperature (including influences of cage mates and bedding), noise, vibration, and disruptions in the home environment (for example, changing or moving the cage). For example, in a recent study, 3 different methods of transferring mice to another cage (forceps transfer, gentle transfer with gloved hands, and a passive transfer technique that did not involve active handling) had transient effects on serum corticosterone concentrations and were associated with altered open-field behaviors when mice were tested later on the same day; these findings indicate that the occurrence of cage change can influence both physiology and patterns of activity.¹⁷⁵ In addition, the frequency at which cages are changed, the type of bedding, and even the color of the caging used can influence the animals and the data collected, including their circadian rhythms and the amount of sleep they engage in.^{46,118,185} With adequate ventilation and bedding, even cages that appear dirty to observers may not have significant or even measurable adverse effects on mice.¹⁸⁵ Furthermore, because rodents are olfactory-oriented

animals, disruption of the olfactory environment in the cage is likely to constitute a significant environmental perturbation that can disrupt stable patterns of activity and behavior.¹⁷⁵ The social environment can affect sleep also, as illustrated in a recent study showing that pair-housed and individually housed mice show differences in their recuperative response to sleep deprivation.¹⁰⁴ Finally, the regulation of ambient light exposure is crucial, as dramatically illustrated in a recent report in which the inadvertent exposure of finches to an abnormal light cycle was associated with the development of clinical illness that resolved when the lighting was corrected.²⁰⁰ Therefore, environmental stability must be controlled carefully by both the husbandry and research staffs to ensure the collection of valid results with minimal numbers of animals. These issues apply to all research that uses animals but are particularly crucial for studies of sleep.

General animal health is important to studies of sleep. Infection, pain and stress, even when subclinical, can alter normal patterns or parameters of sleep and activity in animals and people.^{54,99,215} Because unintended health problems can alter sleep and confound data interpretation, sleep researchers are generally alert for the development of unanticipated changes in the health of their animals and are motivated to correct such problems. Animals that are being used to study sleep and associated behaviors are generally carefully, and often remotely and continuously, monitored for many behavioral and physiologic parameters that reflect overall health. These markers of health and illness can include patterns of sleep, locomotor activity, temperature, and food intake. Indeed, behavioral changes such as reduced activity or food intake are perhaps the most common initial signs of health impairment in clinical veterinary medicine. Because objective measurement of these parameters often occurs continuously in animals on sleep studies, many studies of sleep require surgical implantation of electroencephalographic, electromyographic, and other recording electrodes, which are then monitored by using either tethering or telemetry (for examples, see references 12, 11, 15, 67, 98, 142, 152, 153, 176, 204, and 205). Although appropriate attention to postsurgical care is important to obtaining valid data, many analgesic and antiinflammatory drugs have well documented effects on sleep,^{52,126,157,220} and their use may confound the interpretation of data for some studies. Therefore, studies that require surgery must be designed to ensure that ample time is provided so that the effects of drugs used in association with surgery have dissipated before data collection begins.

Some approaches to monitoring sleep rely on assessment of movement or posture (for examples, see references 53, 74, 133, 156, and 201). Although these methods allow high-throughput processing of mice (for example, for drug evaluation or screening of mutant mice) and do not require surgery, they require validation prior to use in animals that may have inherent or treatment-induced alterations in activity, posture, size, and anatomic characteristics. In addition, behavioral assessment does not provide information on alterations in the electroencephalogram and electromyogram that are crucial to the assessment of genetic and pathologic perturbations of sleep. Therefore, some methods of assessing sleep may not be suitable for particular research questions.

Many studies of sleep and sleep disorders use a period of experimental sleep deprivation as a test situation. In general, both people and animals engage in a period of excess sleep, known as a sleep rebound or recuperative sleep, after an enforced delay in the

normal anticipated time of sleep onset. The sleep rebound reflects the normal homeostatic regulation of sleep and is influenced by genetics, environment, and circadian timing. In general, acute short-term sleep loss has no significant adverse health effects, although it can acutely alter glucose metabolism, cause sleepiness, and impair performance in some tasks.^{94,145} However, the health effect of chronic disruption of sleep is increasingly being recognized and is currently an important topic of study.^{114,228} Several approaches have been used to disrupt sleep in laboratory animals. The most widely used method is the so-called 'gentle-handling' technique, which has been applied to rodents, rabbits, and cats and causes loss of both NREMS and REMS. In this approach, the animals are under continuous observation and, whenever they either enter a state of behaviorally or electroencephalography-defined sleep, they are physically roused by actions such as tapping on the cage, providing novel objects, or gentle prodding. As the duration of the deprivation period increases, particularly beyond a few hours during the species' normal rest phase, the intensity or frequency of arousal interventions must be increased to maintain waking. These interventions can be quantified to generate a measure of sleepiness or sleep drive. In some cases, experimenters use repeated brief episodes of handling applied before sleep deprivation to habituate the animals to this procedure. However, a study using 6 d of repeated brief (3 min) handling of C57BL/6J mice during the light phase reported reductions in rest time on all handling days, increased serum corticosterone levels after 6 d (but not 1 d) of handling, and altered subunit composition of NMDA receptors in hippocampus.¹²⁴ Therefore, mice do not appear to habituate to daily brief handling over a 6-d period, and daily handling may alter measures of sleep homeostasis, stress, and receptor composition and signaling.¹²⁴

Two long-standing approaches to creating chronic sleep disruption are the so-called 'disk-over-water' approach, which can produce either total sleep or REMS deprivation,^{15,177,178} and the 'flower-pot' or 'platform' technique, which produces REMS deprivation but also influences SWS.^{84,129,135,136} Increasingly common approaches to reducing sleep involve automated tactile stimulation,^{144,173,174} forced locomotion,^{13,15,72,111,112,130,131} or other automated interventions.^{148,199} Unlike the gentle-handling method, automated methods can easily be imposed for long periods, potentially creating concern about animal wellbeing during the study. For example, rats develop nonspecific signs of illness after 5 or more days of total sleep deprivation.^{68,69} However, sleep is a highly resilient physiologic process, and animals that experience sleep loss or disruption generally recover without obvious harmful after-effects as soon as they are given the opportunity to sleep.

Interpretation of data collected under all approaches to sleep deprivation or fragmentation requires careful consideration of potential nonspecific effects of the activating stimulus, including both the sensory stimulus used (for example, exposure to novel objects) and the requirement for movement. Many studies incorporate an activity-control group comprising animals that are required to perform equivalent amounts of locomotion over a shorter time period, thereby allowing sufficient time for consolidated sleep (for examples, see references 85 and 205).

Conclusion

Animal-based research has been invaluable with regard to the elucidation of mechanisms that underlie sleep, its regulation, and

its disorders. Although subjective aspects of sleep complicate the use of animals for the study of some types of disorders, animals undoubtedly will remain crucial for discovering and validating sleep mechanisms and testing interventions for sleep disorders. Indeed, additional species are now being evaluated with regard to improving the alignment of human and animal sleep characteristics and thereby creating more valid models (for examples, see references 40 and 93). However, the use of any of these model systems requires careful control of nonspecific aspects of the environment to ensure the collection of valid, interpretable data.

Acknowledgments

Supported in part by NIH grant AI080576 and by the Southern Illinois University School of Medicine. We thank Dr Joseph Q Henkle for reviewing a preliminary version of this manuscript.

References

1. **Akintomide GS, Rickards H.** 2011. Narcolepsy: a review. *Neuropsychiatr Dis Treat* 7:507–518.
2. **Allada R, Siegel JM.** 2008. Unearthing the phylogenetic roots of sleep. *Curr Biol* 18:R670–R679.
3. **Allen RP, Pichiatti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J.** 2003. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. *Sleep Med* 4:101–119.
4. **American Academy of Sleep Medicine Task Force.** 1999. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. *Sleep* 22:667–689.
5. **American Sleep Disorders Association, Diagnostic Classification Steering Committee.** 2005. The international classification of sleep disorders: diagnostic and coding manual. Chicago (IL): American Academy of Sleep Medicine.
6. **Andersen ML, Antunes IB, Silva A, Alvarenga TA, Baracat EC, Tufik S.** 2008. Effects of sleep loss on sleep architecture in Wistar rats: gender-specific rebound sleep. *Prog Neuropsychopharmacol Biol Psychiatry* 32:975–983.
7. **Argyropoulos SV, Hicks JA, Nash JR, Bell CJ, Rich AS, Nutt DJ, Wilson SJ.** 2003. Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. *Psychiatry Res* 120:179–190.
8. **Astori S, Wimmer RD, Prosser HM, Corti C, Corsi M, Liaudet N, Volterra A, Franken P, Adelman JP, Luthi A.** 2011. The Ca(V)3.3 calcium channel is the major sleep spindle pacemaker in thalamus. *Proc Natl Acad Sci USA* 108:13823–13828.
9. **Baier PC, Ondo WG, Winkelmann J.** 2007. Animal studies in restless legs syndrome. *Mov Disord* 22 Suppl. 18:S459–S465.
10. **Balkin TJ, Rupp T, Picchioni D, Wesensten NJ.** 2008. Sleep loss and sleepiness: current issues. *Chest* 134:653–660.
11. **Baracchi F, Ingiosi AM, Raymond RM, Opp MR.** 2011. Sepsis-induced alterations in sleep of rats. *Am J Physiol Regul Integr Comp Physiol* 301:R1467–R1478.
12. **Baracchi F, Opp MR.** 2008. Sleep-wake behavior and responses to sleep deprivation of mice lacking both interleukin 1 β receptor 1 and tumor necrosis factor α receptor 1. *Brain Behav Immun* 22:982–993.
13. **Baud MO, Magistretti PJ, Petit JM.** 2013. Sustained sleep fragmentation affects brain temperature, food intake, and glucose tolerance in mice. *J Sleep Res* 22:3–12.
14. **Benca RM, Bergmann BM, Leung C, Nummy D, Rechtschaffen A.** 1991. Rat strain differences in response to dark pulse triggering of paradoxical sleep. *Physiol Behav* 49:83–87.
15. **Bergmann BM, Kushida CA, Everson CA, Gilliland MA, Obermeyer WH, Rechtschaffen A.** 1989. Sleep deprivation in the rat: II. Methodology. *Sleep* 12:5–12.

16. **Beuckmann CT, Sinton CM, Williams SC, Richardson JA, Hammer RE, Sakurai T, Yanagisawa M.** 2004. Expression of a polyglutamine-ataxin 3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. *J Neurosci* **24**:4469–4477.
17. **Boehmer LN, Wu MF, John J, Siegel JM.** 2004. Treatment with immunosuppressive and antiinflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. *Exp Neurol* **188**:292–299.
18. **Bonnet MH, Arand DL.** 1992. Caffeine use as a model of acute and chronic insomnia. *Sleep* **15**:526–536.
19. **Bonnet MH, Arand DL.** 2010. Hyperarousal and insomnia: state of the science. *Sleep Med Rev* **14**:9–15.
20. **Bourgin P, Zeitler JM, Mignot E.** 2008. CSF hypocretin 1 assessment in sleep and neurological disorders. *Lancet Neurol* **7**:649–662.
21. **Brennick MJ, Kuna ST, Pickup S, Cater J, Schwab RJ.** 2011. Respiratory modulation of the pharyngeal airway in lean and obese mice. *Respir Physiol Neurobiol* **175**:296–302.
22. **Brennick MJ, Pack AI, Ko K, Kim E, Pickup S, Maislin G, Schwab RJ.** 2009. Altered upper airway and soft tissue structures in the New Zealand obese mouse. *Am J Respir Crit Care Med* **179**:158–169.
23. **Brisbare-Roch C, Dingemans J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Naylor C, van Gerven J, de Haas SL, Hess P, Qui C, Buchmann S, Scherz M, Weller T, Fischl W, Clozel M, Jenck F.** 2007. Promotion of sleep by targeting the orexin system in rats, dogs, and humans. *Nat Med* **13**:150–155.
24. **Brooks D, Horner RL, Kimoff J, Kozar LF, Render-Teixeira CL, Phillipson EA.** 1997. Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. *Am J Respir Crit Care Med* **155**:1609–1617.
25. **Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA.** 1997. Obstructive sleep apnea as a cause of systemic hypertension: evidence from a canine model. *J Clin Invest* **99**:106–109.
26. **Broughton R, Mullington J.** 1994. Chronobiological aspects of narcolepsy. *Sleep* **17 Suppl 8**:S35–S44.
27. **Campbell SS, Tobler I.** 1984. Animal sleep: a review of sleep duration across phylogeny. *Neurosci Biobehav Rev* **8**:269–300.
28. **Cano G, Mochizuki T, Saper CB.** 2008. Neural circuitry of stress-induced insomnia in rats. *J Neurosci* **28**:10167–10184.
29. **Carley DW, Berecel K, Videnovic A, Radulovacki M.** 2000. Sleep-disordered respiration in phenotypically normotensive, genetically hypertensive rats. *Am J Respir Crit Care Med* **162**:1474–1479.
30. **Carley DW, Trbovic SM, Radulovacki M.** 1998. Diazepam suppresses sleep apneas in rats. *Am J Respir Crit Care Med* **157**:917–920.
31. **Cederberg R, Nishino S, Dement WC, Mignot E.** 1998. Breeding history of the Stanford colony of narcoleptic dogs. *Vet Rec* **142**:31–36.
32. **Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M.** 1999. Narcolepsy in *orexin* knockout mice: molecular genetics of sleep regulation. *Cell* **98**:437–451.
33. **Chen L, Brown RE, McKenna JT, McCarley RW.** 2009. Animal models of narcolepsy. *CNS Neurol Disord Drug Targets* **8**:296–308.
34. **Chen L, McKenna JT, Bolotuya Y, Winston S, Thakkar MM, Basheer R, Brown RE, McCarley RW.** 2010. Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. *Eur J Neurosci* **32**:1528–1536.
35. **Chen L, Thakkar MM, Winston S, Bolotuya Y, Basheer R, McCarley RW.** 2006. REM sleep changes in rats induced by siRNA-mediated orexin knockdown. *Eur J Neurosci* **24**:2039–2048.
36. **Clark EL, Baumann CR, Cano G, Scammell TE, Mochizuki T.** 2009. Feeding-elicited cataplexy in orexin knockout mice. *Neuroscience* **161**:970–977.
37. **Clemens S, Rye D, Hochman S.** 2006. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. *Neurology* **67**:125–130.
38. **Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Ondo WG, Earley CJ.** 2003. Neuropathological examination suggests im-
- paired brain iron acquisition in restless legs syndrome. *Neurology* **61**:304–309.
39. **Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, Earley CJ.** 2009. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. *Brain* **132**:2403–2412.
40. **Coolen A, Hoffman K, Barf RP, Fuchs E, Meerlo P.** 2012. Telemetric study of sleep architecture and sleep homeostasis in the day-active tree shrew *Tupaia belangeri*. *Sleep* **35**:879–888.
41. **Corner M, van der Togt C.** 2012. No phylogeny without ontogeny: a comparative and developmental search for the sources of sleep-like neural and behavioral rhythms. *Neurosci Bull* **28**:25–38.
42. **Crocker A, Espana RA, Papadopoulou M, Saper CB, Sakurai T, Honda M, Mignot E, Scammell TE.** 2005. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. *Neurology* **65**:1184–1188.
43. **Daan S, Spoelstra K, Albrecht U, Schmutz I, Daan M, Daan B, Rienks F, Poletaeva I, Dell’Omo G, Vysotski A, Lipp HP.** 2011. Lab mice in the field: unorthodox daily activity and effects of a dysfunctional circadian clock allele. *J Biol Rhythms* **26**:118–129.
44. **Daszuta A, Gambarelli F, Ternaux JP.** 1983. Sleep variations in C57BL and BALBc mice from 3 weeks to 14 weeks of age. *Brain Res* **283**:87–96.
45. **Datta S, Maclean RR.** 2007. Neurobiological mechanisms for the regulation of mammalian sleep-wake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence. *Neurosci Biobehav Rev* **31**:775–824.
46. **Dauchy RT, Dauchy EM, Hanifin JP, Gauthreaux SL, Mao L, Belancio VP, Ooms TG, Dupepe LM, Jablonski MR, Warfield B, Wren MA, Brainard GC, Hill SM, Blask DE.** 2013. Effects of spectral transmittance through standard laboratory cages on circadian metabolism and physiology in nude rats. *J Am Assoc Lab Anim Sci* **52**:146–156.
47. **Dean T, Allen RP, O’Donnell CP, Earley CJ.** 2006. The effects of dietary iron deprivation on murine circadian sleep architecture. *Sleep Med* **7**:634–640.
48. **Deboer T.** 2007. Technologies of sleep research. *Cell Mol Life Sci* **64**:1227–1235.
49. **Dematteis M, Godin-Ribout D, Arnaud C, Ribout C, Stanke-Labesque F, Pepin JL, Levy P.** 2009. Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding of the human disease. *ILAR J* **50**:262–281.
50. **Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP.** 2010. Pathophysiology of sleep apnea. *Physiol Rev* **90**:47–112.
51. **Diniz Behn CG, Booth V.** 2011. Modeling the temporal architecture of rat sleep-wake behavior. *Conf Proc IEEE Eng Med Biol Soc* **2011**:4713–4716.
52. **Dispersyn G, Pain L, Touitou Y.** 2009. Circadian disruption of body core temperature and rest-activity rhythms after general (propofol) anesthesia in rats. *Anesthesiology* **110**:1305–1315.
53. **Donohue KD, Medonza DC, Crane ER, O’Hara BF.** 2008. Assessment of a noninvasive high-throughput classifier for behaviours associated with sleep and wake in mice. *Biomed Eng Online* **7**:14.
54. **Doufas AG, Panagiotou OA, Ioannidis JP.** 2012. Concordance of sleep and pain outcomes of diverse interventions: an umbrella review. *PLoS ONE* **7**:e40891.
55. **Dowling P, Klinker F, Stadelmann C, Hasan K, Paulus W, Liebetanz D.** 2011. Dopamine D3 receptor specifically modulates motor and sensory symptoms in iron-deficient mice. *J Neurosci* **31**:70–77.
56. **Drake C, Roehrs T, Breslau N, Johnson E, Jefferson C, Scofield H, Roth T.** 2010. The 10-year risk of verified motor vehicle crashes in relation to physiologic sleepiness. *Sleep* **33**:745–752.
57. **Dreifuss FE, Flynn DV.** 1984. Narcolepsy in a horse. *J Am Vet Med Assoc* **184**:131–132.
58. **Duncan MJ, Smith JT, Franklin KM, Beckett TL, Murphy MP, St Clair DK, Donohue KD, Striz M, O’Hara BF.** 2012. Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer’s disease. *Exp Neurol* **236**:249–258.

59. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. 2000. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. *Neurology* **54**:1698–1700.
60. Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas R, Brasic J, Ravert HT, Dannals RF, Allen RP. 2011. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. *Sleep* **34**:341–347.
61. Eichling PS, Sahni J. 2005. Menopause-related sleep disorders. *J Clin Sleep Med* **1**:291–300.
62. Ekblom K, Ulfberg J. 2009. Restless legs syndrome. *J Intern Med* **266**:419–431.
63. Eleftheriou BE, Zolovick AJ, Elias MF. 1975. Electroencephalographic changes with age in male mice. *Gerontologia* **21**:21–30.
64. Eschenko O, Ramadan W, Molle M, Born J, Sara SJ. 2008. Sustained increase in hippocampal sharp-wave ripple activity during slow-wave sleep after learning. *Learn Mem* **15**:222–228.
65. Espana RA, McCormack SL, Mochizuki T, Scammell TE. 2007. Running promotes wakefulness and increases cataplexy in *orexin* knockout mice. *Sleep* **30**:1417–1425.
66. Esteves AM, de Melio MT, Lancellotti CL, Natal CL, Tufik S. 2004. Occurrence of limb movement during sleep in rats with spinal cord injury. *Brain Res* **1017**:32–38.
67. Everson CA. 1993. Sustained sleep deprivation impairs host defense. *Am J Physiol* **265**:R1148–R1154.
68. Everson CA. 1995. Functional consequences of sustained sleep deprivation in the rat. *Behav Brain Res* **69**:43–54.
69. Everson CA, Toth LA. 2000. Systemic bacterial invasion induced by sleep deprivation. *Am J Physiol Regul Integr Comp Physiol* **278**:R905–R916.
70. Faraco J, Lin X, Hinton L, Lin L, Mignot E. 1999. Genetic studies in narcolepsy, a disorder affecting REM sleep. *J Hered* **90**:129–132.
71. Farre R, Rotger M, Montserrat JM, Calero G, Navajas D. 2003. Collapsible upper airway segment to study the obstructive sleep apnea–hypopnea syndrome in rats. *Respir Physiol Neurobiol* **136**:199–209.
72. Fenzl T, Romanowski CP, Flachskamm C, Honsberg K, Boll E, Hoehna A, Kimura M. 2007. Fully automated sleep deprivation in mice as a tool in sleep research. *J Neurosci Methods* **166**:229–235.
73. Fewell JE, Williams BJ, Szabo JS, Taylor BJ. 1988. Influence of repeated upper airway obstruction on the arousal and cardiopulmonary response to upper airway obstruction in lambs. *Pediatr Res* **23**:191–195.
74. Fisher SP, Godinho SI, Potheary CA, Hankins MW, Foster RG, Peirson SN. 2012. Rapid assessment of sleep–wake behavior in mice. *J Biol Rhythms* **27**:48–58.
75. Fitzpatrick K, Winrow CJ, Gotter AL, Millstein J, Arbuzova J, Brunner J, Kasarskis A, Vitaterna MH, Renger JJ, Turek FW. 2012. Altered sleep and affect in the neurotensin receptor 1 knockout mouse. *Sleep* **35**:949–956.
76. Fletcher EC. 2001. Invited review: physiological consequences of intermittent hypoxia—systemic blood pressure. *J Appl Physiol* **90**:1600–1605.
77. Fletcher EC, Bao G. 1996. The rat as a model of chronic recurrent episodic hypoxia and effect upon systemic blood pressure. *Sleep* **19 Suppl** **10**:S210–S212.
78. Fletcher EC, Bao G, Miller CC. 1995. Effect of recurrent episodic hypocapnic, eucapnic, and hypercapnic hypoxia on systemic blood pressure. *J Appl Physiol* **78**:1516–1521.
79. Foutz AS, Mitler MM, Cavalli-Sforza LL, Dement WC. 1979. Genetic factors in canine narcolepsy. *Sleep* **1**:413–421.
80. Franken P, Malafosse A, Tafti M. 1999. Genetic determinants of sleep regulation in inbred mice. *Sleep* **22**:155–169.
81. Fujiki N, Yoshida Y, Zhang S, Sakurai T, Yanagisawa M, Nishino S. 2006. Sex difference in body weight gain and leptin signaling in hypocretin–orexin-deficient mouse models. *Peptides* **27**:2326–2331.
82. Gerashchenko D, Blanco-Centurion C, Greco MA, Shiromani PJ. 2003. Effects of lateral hypothalamic lesion with the neurotoxin hypocretin-2–saporin on sleep in Long–Evans rats. *Neuroscience* **116**:223–235.
83. Girardeau G, Benchenana K, Wiener SI, Buzsaki G, Zugaro MB. 2009. Selective suppression of hippocampal ripples impairs spatial memory. *Nat Neurosci* **12**:1222–1223.
84. Grahstedt S, Ursin R. 1985. Platform sleep deprivation affects deep slow-wave sleep in addition to REM sleep. *Behav Brain Res* **18**:233–239.
85. Guzman-Marín R, Suntsova N, Stewart DR, Gong H, Szymusiak R, McGinty D. 2003. Sleep deprivation reduces proliferation of cells in the dentate gyrus of the hippocampus in rats. *J Physiol* **549**:563–571.
86. Hamet P, Tremblay J. 2006. Genetics of the sleep–wake cycle and its disorders. *Metabolism* **55 Suppl** **2**:S7–S12.
87. Hamrahi H, Chan B, Horner RL. 2001. Online detection of sleep–wake states and application to produce intermittent hypoxia only in sleep in rats. *J Appl Physiol* **90**:2130–2140.
88. Hamrahi H, Stephenson R, Mahamed S, Liao KS, Horner RL. 2001. Regulation of sleep–wake states in response to intermittent hypoxic stimuli applied only in sleep. *J Appl Physiol* **90**:2490–2501.
89. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T. 2001. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. *Neuron* **30**:345–354.
90. Harvey AG, Tang NK. 2012. (Mis)perception of sleep in insomnia: a puzzle and a resolution. *Psychol Bull* **138**:77–101.
91. Hendricks JC, Kline LR, Kovalski RJ, O’Brien JA, Morrison AR, Pack AI. 1987. The English bulldog: a natural model of sleep-disordered breathing. *J Appl Physiol* **63**:1344–1350.
92. Hendricks JC, Kovalski RJ, Kline LR. 1991. Phasic respiratory muscle patterns and sleep-disordered breathing during rapid eye movement sleep in the English bulldog. *Am Rev Respir Dis* **144**:1112–1120.
93. Hoffmann K, Coolen A, Schlumbohm C, Meerlo P, Fuchs E. 2012. Remote long-term registrations of sleep–wake rhythms, core body temperature, and activity in marmoset monkeys. *Behav Brain Res* **235**:113–123.
94. Horne JA, Reid JA. 1985. Night-time sleep EEG changes following body heating in a warm bath. *Electroencephalogr Clin Neurophysiol* **60**:154–157.
95. Horner RL, Brooks D, Kozar LF, Leung E, Hamrahi H, Render-Teixeria CL, Makino H, Kimoff RJ, Phillipson EA. 1998. Sleep architecture in a canine model of obstructive sleep apnea. *Sleep* **21**:847–858.
96. Huang ZL, Urade Y, Hayaishi O. 2007. Prostaglandins and adenosine in the regulation of sleep and wakefulness. *Curr Opin Pharmacol* **7**:33–38.
97. Hungs M, Mignot E. 2001. Hypocretin–orexin, sleep, and narcolepsy. *Bioessays* **23**:397–408.
98. Imeri L, Bianchi S, Opp MR. 2005. Antagonism of corticotropin-releasing hormone alters serotonergic-induced changes in brain temperature, but not sleep, of rats. *Am J Physiol Regul Integr Comp Physiol* **289**:R1116–R1123.
99. Irwin MR. 2008. Human psychoneuroimmunology: 20 years of discovery. *Brain Behav Immun* **22**:129–139.
100. Jakubcakova V, Flachskamm C, Landgraf R, Kimura M. 2012. Sleep phenotyping in a mouse model of extreme trait anxiety. *PLoS ONE* **7**:e40625.
101. Jun J, Polotsky VY. 2007. Sleep-disordered breathing and metabolic effects: evidence from animal models. *Sleep Med Clin* **2**:263–277.
102. Kaitin KI, Kilduff TS, Dement WC. 1986. Evidence for excessive sleepiness in canine narcoleptics. *Electroencephalogr Clin Neurophysiol* **64**:447–454.
103. Kanagy NL. 2009. Vascular effects of intermittent hypoxia. *ILAR J* **50**:282–288.
104. Kaushal N, Nair D, Gozal D, Ramesh V. 2012. Socially isolated mice exhibit a blunted homeostatic sleep response to acute sleep deprivation compared to socially paired mice. *Brain Res* **1454**:65–79.

105. Kimoff RJ, Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Champagne V, Mayer P, Phillipson EA. 1997. Ventilatory and arousal responses to hypoxia and hypercapnia in a canine model of obstructive sleep apnea. *Am J Respir Crit Care Med* 156:886–894.
106. Knecht CD, Oliver JE, Redding R, Selcer R, Johnson G. 1973. Narcolepsy in a dog and a cat. *J Am Vet Med Assoc* 162:1052–1053.
107. Kushida CA, Baker TL, Dement WC. 1985. Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. *Electroencephalogr Clin Neurophysiol* 61:61–70.
108. Lancel M, van Riezen H, Glatt A. 1991. Effects of circadian phase and duration of sleep deprivation on sleep and EEG power spectra in the cat. *Brain Res* 548:206–214.
109. Landolt HP. 2008. Sleep homeostasis: a role for adenosine in humans? *Biochem Pharmacol* 75:2070–2079.
110. Launois SH, Averill N, Abraham JH, Kirby DA, Weiss JW. 2001. Cardiovascular responses to nonrespiratory and respiratory arousals in a porcine model. *J Appl Physiol* 90:114–120.
111. Leenaars CH, Dematteis M, Joosten RN, Eggels L, Sandberg H, Schirris M, Feenstra MG, van Someren EJ. 2011. A new automated method for rat sleep deprivation with minimal confounding effects on corticosterone and locomotor activity. *J Neurosci Methods* 196:107–117.
112. Leenaars CH, Joosten RN, Zwart A, Sandberg H, Ruimschotel E, Hanegraaf MA, Dematteis M, Feenstra MG, van Someren EJ. 2012. Switch-task performance in rats is disturbed by 12 h of sleep deprivation but not by 12 h of sleep fragmentation. *Sleep* 35:211–221.
113. Leger D, Poursain B, Neubauer D, Uchiyama M. 2008. An international survey of sleeping problems in the general population. *Curr Med Res Opin* 24:307–317.
114. Leproult R, Van Cauter E. 2010. Role of sleep and sleep loss in hormonal release and metabolism. *Endocr Dev* 17:11–21.
115. Lesku JA, Roth TC, Amlaner CJ, Lima SL. 2006. A phylogenetic analysis of sleep architecture in mammals: the integration of anatomy, physiology, and ecology. *Am Nat* 168:441–453.
116. Lesku JA, Roth TC, Rattenborg NC, Amlaner CJ, Lima SL. 2008. Phylogenetics and the correlates of mammalian sleep: a reappraisal. *Sleep Med Rev* 12:229–244.
117. Lesku JA, Roth TC, Rattenborg NC, Amlaner CJ, Lima SL. 2009. History and future of comparative analyses in sleep research. *Neurosci Biobehav Rev* 33:1024–1036.
118. Leys LJ, McGaraghty S, Radek RJ. 2012. Rats housed on corn cob bedding show less slow-wave sleep. *J Am Assoc Lab Anim Sci* 51:764–768.
119. Li C, Balluz LS, Okoro CA, Strine TW, Lim JM, Town M, Garvin W, Murphy W, Bartoli W, Valluru B. 2011. Surveillance of certain health behaviors and conditions among states and selected local areas—Behavioral Risk Factor Surveillance System, United States, 2009. *MMWR Surveill Summ* 60:1–250.
120. Lim DC, Veasey SC. 2010. Neural injury in sleep apnea. *Curr Neurol Neurosci Rep* 10:47–52.
121. Lin L, Faracao J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. 1999. The sleep disorder canine narcolepsy is caused by a mutation in the *hypocretin (orexin) receptor 2* gene. *Cell* 98:365–376.
122. Lin L, Hungs M, Mignot E. 2001. Narcolepsy and the HLA region. *J Neuroimmunol* 117:9–20.
123. Lonergan RP, Ware JC, Atkinson RL, Winter WC, Surat PM. 1998. Sleep apnea in obese miniature pigs. *J Appl Physiol* 84:531–536.
124. Longordo F, Fan J, Steimer T, Kopp C, Luthi A. 2011. Do mice habituate to ‘gentle handling?’ A comparison of resting behavior, corticosterone levels, and synaptic function in handled and undisturbed C57BL/6J mice. *Sleep* 34:679–681.
125. Lu J, Greco MA, Shiromani PJ, Saper CB. 2000. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. *J Neurosci* 20:3830–3842.
126. Lu J, Nelson LE, Franks N, Maze M, Chamberlin NL, Saper CB. 2008. Role of endogenous sleep–wake and analgesic systems in anesthesia. *J Comp Neurol* 508:648–662.
127. Lunn DP, Cuddon PA, Shaftoe S, Archer RM. 1993. Familial occurrence of narcolepsy in miniature horses. *Equine Vet J* 25:483–487.
128. Luo F, Li C, Ondo WG, Xu P, Xie W, Le W. 2011. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model. *Sleep Med* 12:41–46.
129. Machado RB, Suchecki D, Tufik S. 2006. Comparison of the sleep pattern throughout a protocol of chronic sleep restriction induced by 2 methods of paradoxical sleep deprivation. *Brain Res Bull* 70:213–220.
130. McCoy JG, Tartar JL, Bebis AC, Ward CP, McKenna JT, Baxter MG, McGaughy J, McCarley RW, Strecker RE. 2007. Experimental sleep fragmentation impairs attentional set-shifting in rats. *Sleep* 30:52–60.
131. McKenna JT, Tartar JL, Ward CP, Thakkar MM, Cordeira JW, McCarley RW, Strecker RE. 2007. Sleep fragmentation elevates behavioral, electrographic, and neurochemical measures of sleepiness. *Neuroscience* 146:1462–1473.
132. McNamara P, Capellini I, Harris E, Nunn CL, Barton RA, Preston B. 2008. The phylogeny of sleep database: a new resource for sleep scientists. *Open Sleep J* 1:11–14.
133. McShane BB, Galante RJ, Biber M, Jensen ST, Wyner AJ, Pack AI. 2012. Assessing REM sleep in mice using video data. *Sleep* 35:433–442.
134. McWhirter D, Bae C, Budur K. 2007. The assessment, diagnosis, and treatment of excessive sleepiness: practical considerations for the psychiatrist. *Psychiatry (Edgmont)* 4:26–35.
135. Medeiros R, Lennenberg-Hoshino C, Hoshino K, Tufik S. 1998. Neuroethologic differences in sleep deprivation induced by the single- and multiple-platform methods. *Braz J Med Biol Res* 31:675–680.
136. Mendelson WB, Guthrie RD, Frederick G, Wyatt RJ. 1974. The flower-pot technique of rapid eye movement (REM) sleep deprivation. *Pharmacol Biochem Behav* 2:553–556.
137. Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T. 2011. Differential roles of orexin receptors 1 and 2 in the regulation of nonREM and REM sleep. *J Neurosci* 31:6518–6526.
138. Mitler MM, Dement WC. 1977. Sleep studies on canine narcolepsy: pattern and cycle comparisons between affected and normal dogs. *Electroencephalogr Clin Neurophysiol* 43:691–699.
139. Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi K. 2005. CSF iron, ferritin, and transferrin levels in restless legs syndrome. *J Sleep Res* 14:43–47.
140. Mong JA, Baker FC, Mahoney MM, Paul KN, Schwartz MD, Semba K, Silver R. 2011. Sleep, rhythms, and the endocrine brain: influence of sex and gonadal hormones. *J Neurosci* 31:16107–16116.
141. Morin CM, Benca R. 2012. Chronic insomnia. *Lancet* 379:1129–1141.
142. Morrow JD, Opp MR. 2005. Diurnal variation of lipopolysaccharide-induced alterations in sleep and body temperature of interleukin-6-deficient mice. *Brain Behav Immun* 19:40–51.
143. Naidoo N, Ferber M, Galante RJ, McShane B, Hu JH, Zimmerman J, Maislin G, Cater J, Wyner A, Worley P, Pack AI. 2012. Role of Homer proteins in the maintenance of sleep–wake states. *PLoS ONE* 7:e35174.
144. Nair D, Zhang SX, Ramesh V, Hakim F, Kaushal N, Wang Y, Gozal D. 2011. Sleep fragmentation induces cognitive deficits via nicotinamide adenine dinucleotide phosphate oxidase-dependent pathways in mouse. *Am J Respir Crit Care Med* 184:1305–1312.
145. Naitoh P, Kelly TL, Englund C. 1990. Health effects of sleep deprivation. *Occup Med* 5:209–237.
146. Neu D, Mairesse O, Hoffmann G, Dris A, Lambrecht LJ, Linkowski P, Verbanck P, Le Bon O. 2007. Sleep-quality perception in the chronic fatigue syndrome: correlations with sleep efficiency, affective symptoms, and intensity of fatigue. *Neuropsychobiology* 56:40–46.
147. Neubauer JA. 2001. Physiological and pathophysiological responses to intermittent hypoxia. *J Appl Physiol* 90:1593–1599.

148. Newman SM, Paletz EM, Obermeyer EH, Benca RM. 2009. Sleep deprivation in pigeons and rats using motion detection. *Sleep* 32:1299–1312.
149. Nishino S, Reihl J, Hong J, Kwan M, Reid M, Mignot E. 2000. Is narcolepsy a REM sleep disorder? Analysis of sleep abnormalities in narcoleptic Dobermans. *Neurosci Res* 38:437–446.
150. Ohayon MM, O'Hara R, Vitiello MV. 2012. Epidemiology of restless legs syndrome: a synthesis of the literature. *Sleep Med Rev* 16:283–295.
151. Okuma T, Matsuoka H, Matsue Y, Toyomura K. 1982. Model insomnia by methylphenidate and caffeine and use in the evaluation of temazepam. *Psychopharmacology (Berl)* 76:201–208.
152. Olivadoti MD, Opp MR. 2008. Effects of ICV administration of interleukin 1 on sleep and body temperature of interleukin-6-deficient mice. *Neuroscience* 153:338–348.
153. Olivadoti MD, Weinberg JB, Toth LA, Opp MR. 2011. Sleep and fatigue in mice infected with murine gammaherpesvirus 68. *Brain Behav Immun* 25:696–705.
154. Ondo WG, He Y, Rajasekaran S, Le WD. 2000. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. *Mov Disord* 15:154–158.
155. Ondo WG, Zhao HR, Le WD. 2007. Animal models of restless legs syndrome. *Sleep Med* 8:344–348.
156. Pack AI, Galante RJ, Maislin G, Cater J, Metaxas D, Lu S, Zhang L, Von Smith R, Kay T, Lian J, Svenson K, Peters LL. 2007. Novel method for high-throughput phenotyping of sleep in mice. *Physiol Genomics* 28:232–238.
157. Panagiotou I, Mystakidou K. 2012. Nonanalgesic effects of opioids: opioids' effects on sleep (including sleep apnea). *Curr Pharm Des* 18:6025–6033.
158. Panksepp J. 2007. Neuroevolutionary sources of laughter and social joy: modeling primal human laughter in laboratory rats. *Behav Brain Res* 182:231–244.
159. Paterson LM, Nutt DJ, Wilson SJ. 2011. Sleep and its disorders in translational medicine. *J Psychopharmacol* 25:1226–1234.
160. Paterson LM, Wilson SJ, Nutt DJ, Hutson PH. 2007. A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. *Psychopharmacology (Berl)* 191:943–950.
161. Paul KN, Turek FW, Kryger MH. 2008. Influence of sex on sleep regulatory mechanisms. *J Womens Health (Larchmt)* 17:1201–1208.
162. Perlis M, Shaw PJ, Cano G, Espie CA. 2011. Models of insomnia, p 850–865. In: Kryger MH, Roth T, Dement WC, editors. *Principles and practice of sleep medicine*. Philadelphia (PA): WB Saunders.
163. Philip P, Gross CE, Taillard J, Bioulac B, Guilleminault C. 2005. An animal model of a spontaneously reversible obstructive sleep apnea syndrome in the monkey. *Neurobiol Dis* 20:428–431.
164. Phillips BA, Collop NA, Drake C, Consens F, Vgontzas AN, Weaver TE. 2008. Sleep disorders and medical conditions in women. *J Womens Health (Larchmt)* 17:1191–1199.
165. Phillipson EA, Bowes G, Sullivan CE, Woolf GM. 1980. The influence of sleep fragmentation on arousal and ventilatory responses to respiratory stimuli. *Sleep* 3:281–288.
166. Pinto JM, Garpestad E, Weiss JW, Bergau DM, Kirby DA. 1993. Hemodynamic changes associated with obstructive sleep apnea followed by arousal in a porcine model. *J Appl Physiol* 75:1439–1443.
167. Polotsky M, Elsayed-Ahmed AS, Pichard L, Richardson RA, Smith PL, Schneider H, Kirkness JP, Polotsky V, Schwartz AR. 2011. Effect of age and weight on upper airway function in a mouse model. *J Appl Physiol* 111:696–703.
168. Polotsky VY, Rubin AE, Balbir A, Dean T, Smith PL, Schwartz AR, O'Donnell CP. 2006. Intermittent hypoxia causes REM sleep deficits and decreases EEG delta power in NREM sleep in the C57BL/6j mouse. *Sleep Med* 7:7–16.
169. Porkka-Heiskanen T, Alanko L, Kalinchuk A, Stenberg D. 2002. Adenosine and sleep. *Sleep Med Rev* 6:321–332.
170. Qu S, Le W, Zhang X, Xie W, Zhang A, Ondo WG. 2007. Locomotion is increased in a11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. *J Neuropathol Exp Neurol* 66:383–388.
171. Qu WM, Huang ZL, Xu XH, Aritake K, Eguchi N, Nambu F, Narumiya S, Urade Y, Hayaishi O. 2006. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. *Proc Natl Acad Sci USA* 103:17949–17954.
172. Ralls FM, Grigg-Damberger M. 2012. Roles of gender, age, race-ethnicity, and residential socioeconomic in obstructive sleep apnea syndromes. *Curr Opin Pulm Med* 18:568–573.
173. Ramesh V, Kaushal N, Gozal D. 2009. Sleep fragmentation differentially modifies EEG δ power during slow-wave sleep in socially isolated and paired mice. *Sleep Science* 2:64–75.
174. Ramesh V, Nair D, Zhang SX, Hakim F, Kaushal N, Kayali F, Wang Y, Li RC, Carreras A, Gozal D. 2012. Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor α pathway. *J Neuroinflammation* 9:91.
175. Rasmussen S, Miller MM, Filipowski SB, Tolwani RJ. 2011. Cage change influences serum corticosterone and anxiety-like behaviors in the mouse. *J Am Assoc Lab Anim Sci* 50:479–483.
176. Ray MA, Trammell RA, Verhulst S, Ran S, Toth LA. 2011. Model development for the assessment of fatigue during chemotherapy in mice. *Comp Med* 61:119–130.
177. Rechtschaffen A, Bergmann BM. 1995. Sleep deprivation in the rat by the disk-over-water method. *Behav Brain Res* 69:55–63.
178. Rechtschaffen A, Bergmann BM, Everson CA, Kushida CA, Gilliland MA. 1989. Sleep deprivation in the rat: X. Integration and discussion of the findings. *Sleep* 12:68–87.
179. Reid MS, Tafti M, Geary JN, Nishino S, Siegel JM, Dement WC, Mignot E. 1994. Cholinergic mechanisms in canine narcolepsy, I. Modulation of cataplexy via local drug administration into the pontine reticular formation. *Neuroscience* 59:511–522.
180. Revel FG, Gottowik J, Gatti S, Wettstein JG, Moreau JL. 2009. Rodent models of insomnia: a review of experimental procedures that induce sleep disturbances. *Neurosci Biobehav Rev* 33:874–899.
181. Rial RV, Akaarir M, Gamundi A, Nicolau C, Garau C, Aparicio S, Tejada S, Gene L, Gonzalez J, De Vera LM, Coenen AM, Barcelo P, Esteban S. 2010. Evolution of wakefulness, sleep, and hibernation: from reptiles to mammals. *Neurosci Biobehav Rev* 34:1144–1160.
182. Rial RV, Nicolau C, Gamundi A, Akaarir M, Aparicio S, Garau C, Tejada S, Boca C, Gene L, Moranta D, Esteban S. 2007. The trivial function of sleep. *Sleep Med Rev* 11:311–325.
183. Rial RV, Nicolau CM, Gamundi A, Akaarir M, Aparicio S, Garau C, Barcelo P, Esteban S. 2012. REM sleep could have no adaptive value. *Sleep Med Rev* 16:109.
184. Richardson GS. 2007. Human physiological models of insomnia. *Sleep Med* 8 Suppl. 4:S9–S14.
185. Rosenbaum MD, VandeWoude S, Johnson TE. 2009. Effects of cage-change frequency and bedding volume on mice and their microenvironment. *J Am Assoc Lab Anim Sci* 48:763–773.
186. Rubin AE, Polotsky VY, Balbir A, Krishnan JA, Schwartz AR, Smith PL, Fitzferald RS, Tankersley CG, Shirahata M, O'Donnell CP. 2003. Differences in sleep-induced hypoxia between A/J and DBA/2J mouse strains. *Am J Respir Crit Care Med* 168:1520–1527.
187. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. 2007. Chronic intermittent hypoxia induces atherosclerosis. *Am J Respir Crit Care Med* 175:1290–1297.
188. Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, Torbenon MS, Polotsky VY. 2007. Chronic intermittent hypoxia predisposes to liver injury. *Hepatology* 45:1007–1013.
189. Scammell TE, Willie JT, Guilleminault C, Siegel JM. 2009. A consensus definition of cataplexy in mouse models of narcolepsy. *Sleep* 32:111–116.
190. Scharf SM, Graver LM, Balaban K. 1992. Cardiovascular effects of periodic occlusions of the upper airways in dogs. *Am Rev Respir Dis* 146:321–329.
191. Schoorlemmer GH, Rossi MV, Tufik S, Cravo SL. 2011. A new method to produce obstructive sleep apnoea in conscious unrestrained rats. *Exp Physiol* 96:1010–1018.

192. **Senthilvel E, Auckley D, Dasarathy J.** 2011. Evaluation of sleep disorders in the primary care setting: history taking compared to questionnaires. *J Clin Sleep Med* 7:41–48.
193. **Serretti A, Benedetti F, Mandelli L, Lorenzi C, Pirovano A, Colombo C, Smeraldi E.** 2003. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. *Am J Med Genet B Neuropsychiatr Genet* 121B:35–38.
194. **Seugnet L, Suzuki Y, Thimgan M, Donlea J, Gimbel SI, Gottschalk L, Duntley SP, Shaw PJ.** 2009. Identifying sleep regulatory genes using a *Drosophila* model of insomnia. *J Neurosci* 29:7148–7157.
195. **Shaw P.** 2003. Awakening to the behavioral analysis of sleep in *Drosophila*. *J Biol Rhythms* 18:4–11.
196. **Siegel JM.** 1995. Phylogeny and the function of REM sleep. *Behav Brain Res* 69:29–34.
197. **Siegel JM.** 2009. Sleep viewed as a state of adaptive inactivity. *Nat Rev Neurosci* 10:747–753.
198. **Siegel JM.** 2011. REM sleep: a biological and psychological paradox. *Sleep Med Rev* 15:139–142.
199. **Sinton CM, Kowakkattu D, Friese RS.** 2009. Validation of a novel method to interrupt sleep in the mouse. *J Neurosci Methods* 184:71–78.
200. **Snyder JM, Molk DN, Treuting PM.** 2013. Increased mortality in a colony of zebra finches exposed to continuous light. *J Am Assoc Lab Anim Sci* 52:In Press.
201. **Storch C, Hohne A, Holsboer F, Ohl F.** 2004. Activity patterns as a correlate for sleep–wake behavior in mice. *J Neurosci Methods* 133:173–179.
202. **Sweeney CR, Hendricks JC, Beech J, Morrison AR.** 1983. Narcolepsy in a horse. *J Am Vet Med Assoc* 183:126–128.
203. **Tafti M, Nishino S, Aldrich MS, Liao W, Dement WC, Mignot E.** 1996. Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in a canine model. *J Neurosci* 16:4588–4595.
204. **Tang X, Orchard SM, Liu X, Sanford LD.** 2004. Effect of varying recording cable weight and flexibility on activity and sleep in mice. *Sleep* 27:803–810.
205. **Tang X, Sanford LD.** 2002. Telemetric recording of sleep and home cage activity in mice. *Sleep* 25:691–699.
206. **Tartar JL, Ward CP, McKenna JT, Thakkar M, Arrigoni E, McCarley RW, Brown RE, Strecker RE.** 2006. Hippocampal synaptic plasticity and spatial learning are impaired in a rat model of sleep fragmentation. *Eur J Neurosci* 23:2739–2748.
207. **Telles SC, Alves RC, Chadi G.** 2011. Periodic limb movements during sleep and restless legs syndrome in patients with ASIA A spinal cord injury. *J Neurol Sci* 303:119–123.
208. **Thakkar MM, Ramesh V, Cape EG, Winston S, Strecker RE, McCarley RW.** 1999. REM sleep enhancement and behavioral cataplexy following orexin (hypocretin) II receptor antisense perfusion in the pontine reticular formation. *Sleep Res Online* 2:112–120.
209. **Tort AB, Scheffer-Teixeira R, Souza BC, Draguhn A, Brankack J.** 2013. θ -associated high-frequency oscillations (110–160 Hz) in the hippocampus and neocortex. *Prog Neurobiol* 100:1–14.
210. **Toth LA, Verhulst SJ.** 2003. Strain differences in sleep patterns of healthy and influenza-infected inbred mice. *Behav Genet* 33:325–336.
211. **Toth LA, Williams RW.** 1999. A quantitative genetic analysis of slow-wave sleep and rapid-eye-movement sleep in CXB recombinant inbred mice. *Behav Genet* 29:329–337.
212. **Trachel L, Tobler I, Achermann P, Borbely AA.** 1991. Sleep continuity and the REM–nonREM cycle in the rat under baseline conditions and after sleep deprivation. *Physiol Behav* 49:575–580.
213. **Tremaine R, Dorrian J, Lack L, Lovato N, Ferguson S, Zhou X, Roach G.** 2010. The relationship between subjective and objective sleepiness and performance during a simulated night shift with a nap countermeasure. *Appl Ergon* 42:52–61.
214. **Unruh ML, Redline S, An MW, Buysse DJ, Nieto FJ, Yeh JL, Newman AB.** 2008. Subjective and objective sleep quality and aging in the sleep heart health study. *J Am Geriatr Soc* 56:1218–1227.
215. **Vandekerckhove M, Cluydts R.** 2010. The emotional brain and sleep: an intimate relationship. *Sleep Med Rev* 14:219–226.
216. **Veasey S.** 2009. Insight from animal models into the cognitive consequences of adult sleep-disordered breathing. *ILAR J* 50:307–311.
217. **Veasey SC, Valladares O, Fenil P, Kapfhamer D, Sanford L, Benington J, Bucan M.** 2000. An automated system for recording and analysis of sleep in mice. *Sleep* 23:1025–1040.
218. **Ward CP, McCoy JG, McKenna JT, Connolly NP, McCarley RW, Strecker RE.** 2009. Spatial learning and memory deficits following exposure to 24 h of sleep fragmentation or intermittent hypoxia in a rat model of obstructive sleep apnea. *Brain Res* 1294:128–137.
219. **Waters KA, Tinworth KD.** 2005. Habituation of arousal responses after intermittent hypercapnic hypoxia in piglets. *Am J Respir Crit Care Med* 171:1305–1311.
220. **Weinhouse GL, Watson PL.** 2009. Sedation and sleep disturbances in the ICU. *Crit Care Clin* 25:539–549.
221. **White SG, Fletcher EC, Miller CC.** 1995. Acute systemic blood pressure elevation in obstructive and nonobstructive breath hold in primates. *J Appl Physiol* 79:324–330.
222. **Wikenheiser AM, Redish DA.** 2013. The balance of forward and backward hippocampal sequences shifts across behavioral states. *Hippocampus* 23:22–29.
223. **Wilkinson K, Shapiro C.** 2012. Nonrestorative sleep: symptom or unique diagnostic entity? *Sleep Med* 13:561–569.
224. **Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Kohlmeier KA, Leonard CS, Richardson JA, Hammer RE, Yanagisawa M.** 2003. Distinct narcolepsy syndromes in *orexin receptor-2* and *orexin* null mice: molecular genetic dissection of nonREM and REM sleep regulatory processes. *Neuron* 38:715–730.
225. **Wisor JP, Jiang P, Striz M, O'Hara BF.** 2009. Effects of ramelteon and triazolam in a mouse genetic model of early morning awakenings. *Brain Res* 1296:46–55.
226. **Yamauchi M, Kimura H, Strohl KP.** 2010. Mouse models of apnea: strain differences in apnea expression and its pharmacologic and genetic modification. *Adv Exp Med Biol* 669:303–307.
227. **Yanik G, Glaum S, Radulovacki M.** 1987. The dose–response effects of caffeine on sleep in rats. *Brain Res* 403:177–180.
228. **Yeh P, Walters AS, Tsuang JW.** 2012. Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. *Sleep Breath* 16:987–1007.
229. **Zaharna M, Guillemainault C.** 2010. Sleep, noise, and health. *Noise Health* 12:64–69.
230. **Zepelin H, Rechtschaffen A.** 1974. Mammalian sleep, longevity, and energy metabolism. *Brain Behav Evol* 10:425–470.
231. **Zepelin H, Siegel JM, Tobler I.** 2005. Mammalian sleep, p 91–100. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. Philadelphia (PA): WB Saunders.
232. **Zhang L, Zhao ZX.** 2007. Objective and subjective measures for sleep disorders. *Neurosci Bull* 23:236–240.
233. **Zhang S, Lin L, Kaur S, Thankachan S, Blanco-Centurion C, Yanagisawa M, Mignot E, Shiromani PJ.** 2007. The development of hypocretin (orexin) deficiency in *hypocretin-ataxin 3* transgenic rats. *Neuroscience* 148:34–43.
234. **Zhang S, Zeitzer JM, Sakurai T, Nishino S, Mignot E.** 2007. Sleep–wake fragmentation disrupts metabolism in a mouse model of narcolepsy. *J Physiol* 581:649–663.
235. **Zhu Y, Fenik P, Zhan G, Mazza E, Kelz M, Aston-Jones G, Veasey SC.** 2007. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. *J Neurosci* 27:10060–10071.